Singapore neurological biomarkers market for Alzheimers disease
generated a revenue of $2,636.7 million in 2017, and is expected to reach
$6,122.5 million by 2025, registering a CAGR of 11.1% from 2018 to 2025.
Conversely, neurological biomarkers market for Parkinsons disease generated a
revenue of $1,321.8 million in 2017, and is expected to reach $2,457.4 million
by 2025 registering a CAGR of 8.0%.
Download Sample Report: https://www.alliedmarketresearch.com/request-sample/3555
Upsurge in the incidence of Alzheimers and Parkinsons
diseases is anticipated to contribute to the robust growth of neurological
biomarkers. In addition, increase in adoption of neurological biomarkers in
drug development and validation has been witnessed over the years to improve
the accuracy of clinical trials. Furthermore, rise in preference towards
personalized medicine is expected to offer profitable opportunities for the
expansion of Singapore neurological biomarkers applied across Alzheimers and Parkinsons.
Based on the region, the Singapore neurological biomarkers market for
Alzheimers and Parkinsons diseases is studied across the U.S., EU5, rest of
Europe, China, Asia-Pacific, and rest of the world (ROW). The U.S. dominated
the market for Alzheimers and Parkinsons in 2017, and is expected to continue
this trend throughout the forecast period. In addition, Asia-Pacific is
anticipated to grow at the fastest pace in Alzheimers neurological biomarkers
market during the forecast period, whereas China is expected to register
highest growth rate from 2018 to 2025 in the Parkinsons neurological biomarkers
market.
Get Detail Report https://www.alliedmarketresearch.com/neurological-biomarkers-market
0 Comments